VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
Formation Bio Doses First Participant in Phase 1 Trial of BLKR201, a CNS-Penetrant TYK2 Inhibitor
Formation Bio Doses First Participant in Phase 1 Trial of BLKR201, a CNS-Penetrant TYK2 Inhibitor
Jun 09, 2026 20:59 CST Updated 21:18
Share:
